Bristol Myers Squibb
Canvas Category OEM : Pharmaceutical
We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Assembly Line
Redwire Announces Spaceflight Mission with Bristol Myers Squibb to Study Small Molecule Drug Compounds, Launching Additional Biopharma Investigations to Study Bone Disease Treatments in Space
Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced that it is launching an investigation to the International Space Station (ISS) in partnership with global leading biopharmaceutical company Bristol Myers Squibb (BMS) to study model small molecule compounds using Redwire’s pharmaceutical drug development platform (PIL-BOX). The research being conducted with BMS has the potential to enhance drug stability, streamline manufacturing processes, and improve efficiencies across various therapeutic areas, including oncology, immunology, and cardiovascular disease.
Additionally, Redwire will be launching a PIL-BOX investigation in partnership with pharmaceutical startup company ExesaLibero Pharma to study the novel drug ELP-004, which prevents excess bone removal associated with numerous diseases, including rheumatoid arthritis, multiple myeloma, and breast and prostate cancers. These newest spaceflight investigations further establish PIL-BOX as the premier space pharmaceutical research platform with 16 PIL-BOXes flown to date and 12 more set to launch on the next commercial resupply mission to the ISS.
A third PIL-BOX investigation launching to the ISS is being conducted in partnership with Butler University. Redwire and Butler University will seek to produce high-quality seed crystals in microgravity that could be used to produce pharmaceuticals on Earth. This is Butler University’s second PIL-BOX investigation.